Summary

Market Overview
The Global market for next-generation biotherapeutics is anticipated to expand from USD 5.71 billion in 2025 to USD 11.65 billion by 2031, reflecting a compound annual growth rate of 12.62%. These advanced treatments involve sophisticated biological systems and molecules sourced from living organisms, encompassing gene and cell therapies, monoclonal antibodies, and oligonucleotide therapeutics. They are formulated to provide highly targeted treatments for ailments such as genetic disorders, cancer, and autoimmune diseases. Growth in this sector is primarily fueled by the rising global incidence of rare and chronic illnesses that necessitate novel medical solutions, alongside major technological strides and boosted funding in biopharmaceutical research and development.
However, continuous market growth is significantly hindered by the steep expenses tied to creating, producing, and distributing these intricate biological treatments. Data from the Pharmaceutical Research and Manufacturers of America indicates that out of 52 new medicines approved in 2025, only six were novel vaccines and biologics. Additionally, the Biotechnology Innovation Organization highlighted in 2025 that financial backing for biotech startups dropped sharply from $2.6 billion in the first quarter to $900 million by the second quarter, emphasizing the tight financial conditions currently impacting the industry.
Market Driver
Progress in therapeutic technologies and biotechnology is significantly transforming the next-generation biotherapeutics industry by facilitating the creation of highly complex medical interventions. Breakthroughs in RNA-based treatments, cell therapy, and gene editing are broadening the range of conditions that can be treated while introducing innovative mechanisms of action. Consequently, an expanding portfolio of sophisticated biological treatments is successfully navigating the regulatory approval process. As noted by Contract Pharma on March 2, 2026, in its report "The 2026 Biologics Wave: Which Innovations Will Break Through?", the CDER had authorized 46 new drug therapies by the close of 2025, a dozen of which were biologics. This trend highlights the growing viability and advancement of next-generation biotherapeutics, which in turn draws more funding and skilled professionals to the field.
An additional major catalyst for this global market is the rising need for customized and highly targeted medical therapies, which signifies a major shift toward individualized patient healthcare. This surge in demand is driven by a more profound comprehension of disease variations and the capacity of these advanced therapies to deliver better results with fewer adverse effects than traditional options. These individualized strategies are especially crucial in challenging medical fields such as rare diseases and oncology. A MarketWatch report from March 27, 2026, titled "Personalized Medicine Market Share & Opportunities 2026-2033," predicts that North America will capture 44.4% of the personalized medicine sector in 2026, demonstrating strong regional uptake. Moreover, massive investments are flowing into the wider biopharmaceutical arena, with Fierce Biotech reporting in 2026 that major pharma corporations spent over $36 billion on biotech buyouts during just October and November of 2025, thereby sustaining the innovation and infrastructure needed to deliver these modern treatments worldwide.
Market Challenge
The immense financial requirements for researching, producing, and distributing next-generation biotherapeutics create a major hurdle for the growth of this market. Because these advanced treatments require in-depth scientific study, custom-built manufacturing centers, and rigorous regulatory compliance, the overall expenditures are exceptionally high. Consequently, this financial strain leads to exorbitant prices for the final therapies, which can restrict availability for a wider range of patients and ultimately hinder broader market acceptance and overall utilization.
Additionally, the massive financial investment necessary to advance these therapies presents a formidable obstacle for emerging biotech startups and smaller enterprises. Obtaining the requisite capital to support lengthy research phases and expansive production efforts proves difficult, especially when investors require rigorous proof of concept beforehand. Data from the Massachusetts Biotechnology Council shows that venture capital funding for companies based in Massachusetts reached $6.85 billion over 197 investment rounds in 2025. Although these figures indicate a recovery to numbers seen before the pandemic, they also highlight a fiercely competitive funding environment that can delay the journey of groundbreaking treatments from the laboratory to the commercial market.
Market Trends
Incorporating artificial intelligence into the creation of new medicines is drastically altering the global next-generation biotherapeutics sector by speeding up discovery and boosting research and development productivity. By moving past conventional lab techniques, this movement utilizes advanced computing to quickly pinpoint new drug targets, engineer better molecules, and forecast both safety and effectiveness. These AI applications are modernizing the initial phases of pharmaceutical development, fostering a more adaptable and data-centric approach. Illustrating the industry's strong confidence in this technological evolution, Eli Lilly and NVIDIA declared in January 2026 that they would co-invest up to $1 billion over a five-year period to establish an AI-driven laboratory dedicated to discovering novel drugs.
A parallel major trend is the rise of localized and point-of-care biological manufacturing systems, which play a vital role in effectively creating and supplying cutting-edge treatments, especially those tailored for rare conditions and personalized medicine. This transition circumvents the high costs and logistical difficulties of massive, centralized production by utilizing compact, adaptable facilities situated near patients or dedicated care facilities. Such frameworks capitalize on advancements like continuous manufacturing to lower the massive upfront investments typically needed to produce biologics. As highlighted by MedCity News on January 29, 2026, utilizing continuous manufacturing methods can shrink the required equipment space by as much as 70%, rendering these decentralized production networks much more cost-effective and functionally beneficial.

Key Market Players
* Xencor, Inc.
* Regenxbio & Neurimmune AG
* Takeda Pharmaceutical Company Limited
* Pfizer, Inc.
* AstraZeneca Plc.
* F. Hoffmann-La Roche Ltd.
* Kyowa Kirin Co., Ltd
* Seattle Genetics, Inc
* ImmunoGen, Inc
* Ono Pharmaceuticals Co, Ltd

Report Scope
In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

# Next Generation Biotherapeutics Market, By Therapeutic Area
* Oncology
* Autoimmune/ Inflammatory Diseases
# Next Generation Biotherapeutics Market, By Technology
* Antibody-Drug Conjugates
* Bispecific Antibodies
* Antibody Fragments
* Antibody-like Proteins
* Others
# Next Generation Biotherapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.
Available Customizations:
Global Next Generation Biotherapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Next Generation Biotherapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases)
5.2.2. By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Next Generation Biotherapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Area
6.2.2. By Technology
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Next Generation Biotherapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Area
6.3.1.2.2. By Technology
6.3.2. Canada Next Generation Biotherapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Area
6.3.2.2.2. By Technology
6.3.3. Mexico Next Generation Biotherapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Area
6.3.3.2.2. By Technology
7. Europe Next Generation Biotherapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutic Area
7.2.2. By Technology
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Next Generation Biotherapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Area
7.3.1.2.2. By Technology
7.3.2. France Next Generation Biotherapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Area
7.3.2.2.2. By Technology
7.3.3. United Kingdom Next Generation Biotherapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Area
7.3.3.2.2. By Technology
7.3.4. Italy Next Generation Biotherapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Area
7.3.4.2.2. By Technology
7.3.5. Spain Next Generation Biotherapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Area
7.3.5.2.2. By Technology
8. Asia Pacific Next Generation Biotherapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutic Area
8.2.2. By Technology
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Next Generation Biotherapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Area
8.3.1.2.2. By Technology
8.3.2. India Next Generation Biotherapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Area
8.3.2.2.2. By Technology
8.3.3. Japan Next Generation Biotherapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Area
8.3.3.2.2. By Technology
8.3.4. South Korea Next Generation Biotherapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Area
8.3.4.2.2. By Technology
8.3.5. Australia Next Generation Biotherapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Area
8.3.5.2.2. By Technology
9. Middle East & Africa Next Generation Biotherapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Area
9.2.2. By Technology
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Next Generation Biotherapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Area
9.3.1.2.2. By Technology
9.3.2. UAE Next Generation Biotherapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Area
9.3.2.2.2. By Technology
9.3.3. South Africa Next Generation Biotherapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Area
9.3.3.2.2. By Technology
10. South America Next Generation Biotherapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Area
10.2.2. By Technology
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Next Generation Biotherapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Area
10.3.1.2.2. By Technology
10.3.2. Colombia Next Generation Biotherapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Area
10.3.2.2.2. By Technology
10.3.3. Argentina Next Generation Biotherapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Area
10.3.3.2.2. By Technology
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Next Generation Biotherapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Xencor, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Regenxbio & Neurimmune AG
15.3. Takeda Pharmaceutical Company Limited
15.4. Pfizer, Inc.
15.5. AstraZeneca Plc.
15.6. F. Hoffmann-La Roche Ltd.
15.7. Kyowa Kirin Co., Ltd
15.8. Seattle Genetics, Inc
15.9. ImmunoGen, Inc
15.10. Ono Pharmaceuticals Co, Ltd
16. Strategic Recommendations
17. About Us & Disclaimer